239 related articles for article (PubMed ID: 15531452)
1. A long-term study of young patients with essential thrombocythemia treated with anagrelide.
Mazzucconi MG; Redi R; Bernasconi S; Bizzoni L; Dragoni F; Latagliata R; Santoro C; Mandelli F
Haematologica; 2004 Nov; 89(11):1306-13. PubMed ID: 15531452
[TBL] [Abstract][Full Text] [Related]
2. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
Fruchtman SM; Petitt RM; Gilbert HS; Fiddler G; Lyne A;
Leuk Res; 2005 May; 29(5):481-91. PubMed ID: 15755500
[TBL] [Abstract][Full Text] [Related]
3. [Anagrelide in the treatment of thrombocythemia essential (ET)].
Mazur G; Wróbel T; Podolak-Dawidziak M; Kuliszkiewicz-Janus M; Potoczek S; Nosol J; Kuliczkowski K
Pol Arch Med Wewn; 2004 Dec; 112(6):1445-50. PubMed ID: 15962609
[TBL] [Abstract][Full Text] [Related]
4. Treatment of essential thrombocythemia in childhood.
Scherer S; Ferrari R; Rister M
Pediatr Hematol Oncol; 2003; 20(5):361-5. PubMed ID: 12775533
[TBL] [Abstract][Full Text] [Related]
5. Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France.
Rey J; Viallard JF; Keddad K; Smith J; Wilde P; Kiladjian JJ;
Eur J Haematol; 2014 Feb; 92(2):127-36. PubMed ID: 24118452
[TBL] [Abstract][Full Text] [Related]
6. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders.
Birgegård G; Björkholm M; Kutti J; Lärfars G; Löfvenberg E; Markevärn B; Merup M; Palmblad J; Mauritzson N; Westin J; Samuelsson J
Haematologica; 2004 May; 89(5):520-7. PubMed ID: 15136214
[TBL] [Abstract][Full Text] [Related]
7. [Treatment outcome of patients with essential thrombocythemia at our department in Hungary].
Iványi JL; Marton É; Plander M; Szendrei T
Orv Hetil; 2016 Feb; 157(9):336-41. PubMed ID: 26895801
[TBL] [Abstract][Full Text] [Related]
8. [Anagrelide in control of myeloproliferative thrombocythemia: long-term experiences in 6 patients].
Burkhard R; Adam H; Widmer L; Honegger HP
Schweiz Med Wochenschr; 1998 Nov; 128(46):1808-12. PubMed ID: 9857387
[TBL] [Abstract][Full Text] [Related]
9. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
Harrison CN; Campbell PJ; Buck G; Wheatley K; East CL; Bareford D; Wilkins BS; van der Walt JD; Reilly JT; Grigg AP; Revell P; Woodcock BE; Green AR;
N Engl J Med; 2005 Jul; 353(1):33-45. PubMed ID: 16000354
[TBL] [Abstract][Full Text] [Related]
10. Long-term use of anagrelide in young patients with essential thrombocythemia.
Storen EC; Tefferi A
Blood; 2001 Feb; 97(4):863-6. PubMed ID: 11159509
[TBL] [Abstract][Full Text] [Related]
11. Therapy with Anagrelide in patients affected by essential thrombocythemia: preliminary results.
Mazzucconi MG; De Sanctis V; Chistolini A; Dragoni F; Mandelli F
Haematologica; 1992; 77(4):315-7. PubMed ID: 1427441
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of essential thrombocythemia with anagrelide: a ten-year experience].
Kornblihtt LI; Vassallu PS; Heller P; Molinas FC
Medicina (B Aires); 2002; 62(3):231-6. PubMed ID: 12150005
[TBL] [Abstract][Full Text] [Related]
13. [Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR].
Penka M; Doubek M; Schwarz J; Pytlík R; Dulícek P; Kissová J; Hlusí A; Vozobulová V; Cerná O; Brychtová Y; Szotkowski T; Volková Z; Seghetová J; Schutzová M; Hadacová I; Hochová I; Voglová J; Siroký O; Belada D; Lhot'anová T; Bubeník B; Vránová M; Micaníková M; Dusek L
Vnitr Lek; 2006 May; 52(5):498-503. PubMed ID: 16771099
[TBL] [Abstract][Full Text] [Related]
14. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders.
Balduini CL; Bertolino G; Noris P; Ascari E
Haematologica; 1992; 77(1):40-3. PubMed ID: 1398280
[TBL] [Abstract][Full Text] [Related]
15. [Anagrelide in primary thrombocythemia].
Knutsen H; Hysing J
Tidsskr Nor Laegeforen; 2001 May; 121(12):1478-82. PubMed ID: 11449771
[TBL] [Abstract][Full Text] [Related]
16. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.
Steurer M; Gastl G; Jedrzejczak WW; Pytlik R; Lin W; Schlögl E; Gisslinger H
Cancer; 2004 Nov; 101(10):2239-46. PubMed ID: 15476273
[TBL] [Abstract][Full Text] [Related]
17. Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany.
Petrides PE; Beykirch MK; Trapp OM
Eur J Haematol; 1998 Aug; 61(2):71-6. PubMed ID: 9714517
[TBL] [Abstract][Full Text] [Related]
18. Anagrelide: a new drug for treating thrombocytosis.
Silverstein MN; Petitt RM; Solberg LA; Fleming JS; Knight RC; Schacter LP
N Engl J Med; 1988 May; 318(20):1292-4. PubMed ID: 3362187
[TBL] [Abstract][Full Text] [Related]
19. [Retrospective analysis of the efficacy and tolerability of anagrelide in patients with essential thrombocytemia: Spanish registry of essential thrombocytemia].
Giralt M; Navas V; Hernández-Nieto L; Burgaleta C; Carbonell F; Ramírez G; Vicente V; Besses C;
Med Clin (Barc); 2009 Jun; 133(3):86-90. PubMed ID: 19501853
[TBL] [Abstract][Full Text] [Related]
20. Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the "Ph1-negative Myeloproliferative Neoplasms Latium Group".
Mazzucconi MG; Baldacci E; Latagliata R; Breccia M; Paoloni F; Di Veroli A; Cedrone M; Anaclerico B; Villivà N; Porrini R; Montefusco E; Andriani A; Montanaro M; Scaramucci L; Spadea A; Rago A; Cimino G; Spirito F; Santoro C
Eur J Haematol; 2020 Sep; 105(3):335-343. PubMed ID: 32441419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
